BioSpace News Archive

The American Diabetes Association® announced its recognition as a winner in the 2022 Sharecare Awards in the category of chronic diseases for The Big Step Up: Detection that encourages people to take the big step up for their health.

Bayer’s KERENDIA® (finerenone) was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a consensus report jointly issued by KDIGO and the American Diabetes Association (ADA).

October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication of YIKAIDA submitted by Fosun Kite Biotechnology Co., Ltd. (hereinafter referred to as Fosun Kite) was approved for review and included in the list for priority review.

Following an extensive international search, Emory University announced that Ravi I. Thadhani, MD, MPH, has been appointed executive vice president for health affairs.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, before the US markets open on Tuesday, November 8, 2022.

A medical device company called Neurocast with offices in Amsterdam, Netherlands, and Cambridge, Massachusetts is taking brain health to heart with the launch of its new platform NeuroKeys

Moderna, Inc. announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers’ 2022 Top Employers Survey for the eighth consecutive year.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its CD38-targeted Flex-NK™ cell engager antibodies at the American Society of Hematology’s 64th Annual Meeting.

Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced yesterday the poster presentation for TOS-358 at the 34th EORTC-NCI-AACR Symposium (ENA 2022) held in Barcelona Oct 26-28, 2022.

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the third quarter ended September 30, 2022.